Clinical trials
Completed Phase 1 trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
963 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 6 |
| 2005 | 2 |
| 2006 | 25 |
| 2007 | 35 |
| 2008 | 54 |
| 2009 | 53 |
| 2010 | 71 |
| 2011 | 68 |
| 2012 | 62 |
| 2013 | 42 |
| 2014 | 62 |
| 2015 | 66 |
| 2016 | 53 |
| 2017 | 73 |
| 2018 | 53 |
| 2019 | 49 |
| 2020 | 52 |
| 2021 | 54 |
| 2022 | 18 |
| 2023 | 27 |
| 2024 | 18 |
| 2025 | 10 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 963 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 81 |
| Astellas Pharma Inc | 61 |
| Eli Lilly and Company | 61 |
| Boehringer Ingelheim | 57 |
| Pfizer | 43 |
| Novartis Pharmaceuticals | 40 |
| Eisai Co., Ltd. | 39 |
| GlaxoSmithKline | 38 |
| Janssen Pharmaceutical K.K. | 35 |
| Novo Nordisk A/S | 33 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 109 |
| Diabetes Mellitus, Type 2 | 34 |
| Carcinoma, Non-Small-Cell Lung | 33 |
| Diabetes Mellitus | 26 |
| Neoplasm Metastasis | 25 |
| Breast Neoplasms | 21 |
| Alzheimer Disease | 20 |
| Leukemia, Myeloid, Acute | 18 |
| Multiple Myeloma | 18 |
| Carcinoma, Hepatocellular | 16 |
Trials
Showing 1 to 25 of 963. Each trial links to its page on Pharma Observatory.
863 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.